Related Experiment Video
Updated: Apr 30, 2026
05:21
Computerized Adaptive Testing System of Functional Assessment of Stroke
Published on: January 7, 2019
5.4K
An assessment by the Statin Cognitive Safety Task Force: 2014 update
Carlos H Rojas-Fernandez1, Larry B Goldstein2, Allan I Levey3
1Schlegel-UW Research Institute for Ageing; School of Public Health and Health Systems; School of Pharmacy, University of Waterloo, 10 Victoria Street S, Room 7004, Kitchener, Ontario N2G 1C5, Canada; Michael G. DeGroote School of Medicine, Department of Family Medicine, McMaster University, University of Waterloo, Hamilton, ON, Canada.
Journal of Clinical Lipidology
|May 6, 2014
Summary
This review found no clear evidence that statins cause cognitive impairment. Experts updated guidelines on statin safety and cognitive function for healthcare providers.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- The National Lipid Association previously assessed statin safety in 2006.
- Concerns persist regarding potential adverse cognitive effects of statins.
- An updated assessment was needed to reflect current evidence.
Purpose of the Study:
- To develop an updated position statement on statin-associated cognitive effects.
- To revise and supersede the 2006 assessment by a panel of neurologists.
- To address the specific issue of potential adverse cognitive effects attributable to statins.
Main Methods:
- A consensus conference convened by the National Lipid Association's Safety Task Force.
- Systematic literature searches (Medline, 1966-2013) and manual bibliography searches.
- Expert panel formulated answers to key questions, grading evidence and recommendations.
Main Results:
- The expert panel reviewed evidence on statins and cognitive function.
- Evidence quality and recommendation strength were graded using contemporary standards.
- The findings inform clinical decision-making and future research.
Conclusions:
- An updated position statement on statin cognitive safety was developed.
- Recommendations were provided for patients, health professionals, and researchers.
- The consensus aimed to clarify the relationship between statins and cognitive function.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
973
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
973
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444